ES2055845T3 - Composicion farmaceutica para el tratamiento de la osteoporosis. - Google Patents
Composicion farmaceutica para el tratamiento de la osteoporosis.Info
- Publication number
- ES2055845T3 ES2055845T3 ES90120567T ES90120567T ES2055845T3 ES 2055845 T3 ES2055845 T3 ES 2055845T3 ES 90120567 T ES90120567 T ES 90120567T ES 90120567 T ES90120567 T ES 90120567T ES 2055845 T3 ES2055845 T3 ES 2055845T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- pharmaceutical composition
- osteoporosis
- estrogen
- thyroid hormone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940011871 estrogen Drugs 0.000 abstract 3
- 239000000262 estrogen Substances 0.000 abstract 3
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 abstract 2
- 239000005495 thyroid hormone Substances 0.000 abstract 2
- 229940036555 thyroid hormone Drugs 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
UN COMPUESTO FARMACEUTICO PARA EL TRATAMIENTO DE OSTEOPOROSIS, COMPRENDE UN ESTREGENO Y UNA HORMONA DE TIROIDE COMO INGREDIENTES EFECTIVOS. UTILIZANDO EL ESTROGENO CON COMBINACION CON LA HORMONA DE TIROIDE, SE PUEDE OBTENER UNA ACTIVIDAD MUCHISIMO MAS GRANDE EN INCREMENTAR LA CANTIDAD DE HUESO QUE EN EL CASO DE SUMINISTRAR SOLAMENTE EL ESTROGENO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP28114189 | 1989-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2055845T3 true ES2055845T3 (es) | 1994-09-01 |
Family
ID=17634937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES90120567T Expired - Lifetime ES2055845T3 (es) | 1989-10-26 | 1990-10-26 | Composicion farmaceutica para el tratamiento de la osteoporosis. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5116828A (es) |
| EP (1) | EP0424954B1 (es) |
| JP (1) | JP3113269B2 (es) |
| AT (1) | ATE104854T1 (es) |
| DE (1) | DE69008476T2 (es) |
| ES (1) | ES2055845T3 (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59309063D1 (de) * | 1992-03-21 | 1998-11-19 | Entec | Verwendung von östriol zur herstellung einen transdermalen therapeutischen systeme zur behandlung von klimakterischer osteoporose |
| DE69331833T2 (de) * | 1992-12-29 | 2002-11-14 | Michael F. Holick | Verwendung von vitamin d-glykosiden zur behandlung oder prävention von osteoporose |
| US5776923A (en) * | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
| PT1382340E (pt) * | 1993-01-19 | 2006-07-31 | Endorech Inc | Utilizacoes terapeuticas de desidroepiandrosterona para tratar libido diminuida e osteoporose |
| US20030170290A1 (en) * | 1993-06-16 | 2003-09-11 | Shug Austin L. | Delayed release carnitine |
| JPH09100293A (ja) * | 1995-10-03 | 1997-04-15 | Kanebo Ltd | インターロイキン8の作用増強剤 |
| JP2000502086A (ja) | 1995-12-13 | 2000-02-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 核レセプターのリガンドおよびリガンド結合ドメイン |
| US6266622B1 (en) * | 1995-12-13 | 2001-07-24 | Regents Of The University Of California | Nuclear receptor ligands and ligand binding domains |
| US6197291B1 (en) | 1996-06-27 | 2001-03-06 | Kanebo Limited | Agent for potentiating the effect of interleukin-8 |
| IT1292129B1 (it) * | 1997-06-11 | 1999-01-25 | Sunnimex Ltd | Medicamento utile per ridurre la massa grassa ed aumentare la massa magra nella donna in menopausa ed in entrambi i sessi nella |
| US6117429A (en) * | 1997-08-11 | 2000-09-12 | Weider Nutrition International, Inc | Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors |
| US6342611B1 (en) * | 1997-10-10 | 2002-01-29 | Cytovia, Inc. | Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof |
| NZ536787A (en) * | 1998-06-11 | 2006-03-31 | Endorech Inc | Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta diol |
| US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| DE10027887A1 (de) * | 2000-05-31 | 2001-12-13 | Jenapharm Gmbh | Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| ITMI20110713A1 (it) | 2011-04-29 | 2012-10-30 | Bracco Imaging Spa | Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina |
| ITMI20022394A1 (it) * | 2002-11-13 | 2004-05-14 | Bracco Spa | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
| EP2428516A1 (en) * | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| DE102004025985A1 (de) * | 2004-05-21 | 2005-12-15 | Schering Ag | Estriol- und Estetrol-Prodrugs |
| US20050277625A1 (en) * | 2004-05-21 | 2005-12-15 | Ralf Wyrwa | Estriol and estetrol prodrugs |
| US7534780B2 (en) * | 2004-05-21 | 2009-05-19 | Bayer Schering Pharma Aktiengesellschaft | Estradiol prodrugs |
| US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
| RU2007148927A (ru) * | 2005-05-26 | 2009-07-10 | Метабэйзис Терапьютикс, Инк. (Us) | Новые тиреомиметики, содержащие фосфиновую кислоту |
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| EP1910402A2 (en) * | 2005-07-12 | 2008-04-16 | Warner Chilcott Company, Inc. | 3-ester prodrugs of estradiol |
| CA2610475C (en) * | 2005-07-12 | 2013-09-17 | Warner Chilcott Company, Inc. | Derivative prodrugs of ethinyl estradiol |
| RS52671B (sr) | 2005-10-12 | 2013-06-28 | Unimed Pharmaceuticals Llc | Poboljšani gel testosterona i postupak korišćenja |
| US20070123500A1 (en) * | 2005-11-29 | 2007-05-31 | Gerd Mueller | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds |
| US20070197488A1 (en) * | 2005-11-29 | 2007-08-23 | Olaf Peters | Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds |
| US20070135375A1 (en) * | 2005-11-30 | 2007-06-14 | Ralf Wyrwa | Sulfamoyl sulfonate prodrugs |
| US8288366B2 (en) | 2006-06-20 | 2012-10-16 | Chochinov Ronald H | Formulation for hair growth |
| CN108130327A (zh) | 2007-10-11 | 2018-06-08 | 第三共株式会社 | 靶向破骨细胞相关蛋白Siglec-15的抗体 |
| WO2010107702A1 (en) * | 2009-03-16 | 2010-09-23 | Ipintl, Llc | Treating alzheimer's disease and osteoporosis and reducing aging |
| WO2018094265A2 (en) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
| AU2018280118B2 (en) | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| EP4775207A2 (en) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| EP4161925A4 (en) | 2020-06-09 | 2024-09-04 | Viking Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES |
| US12235043B1 (en) * | 2024-08-30 | 2025-02-25 | ALI Pharmaceutical Manufacturing, LLC | Desiccated thyroid extract manufacturing method |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6434M (es) * | 1967-02-23 | 1968-11-04 | ||
| US4041022A (en) * | 1967-05-24 | 1977-08-09 | Ciba-Geigy Corporation | Process for the manufacture of thyrocalcitonin |
| GB2138286B (en) * | 1983-04-19 | 1986-10-08 | Dr Christopher Harry Mortimer | Pharmaceutical composition for the treatment of hair loss |
| US4692433A (en) * | 1983-10-12 | 1987-09-08 | The Regents Of The University Of California | Method and composition for regulating serum calcium levels of mammals |
| JPS6089422A (ja) * | 1983-10-24 | 1985-05-20 | Kureha Chem Ind Co Ltd | 抗骨粗鬆症剤 |
| US4822609A (en) * | 1984-12-21 | 1989-04-18 | The Procter & Gamble Company | Treatment of osteoporosis |
| US4812304A (en) * | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Treatment of osteoporosis |
| US4812311A (en) * | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Kit for use in the treatment of osteoporosis |
| US5001118A (en) * | 1986-12-29 | 1991-03-19 | Kureha Kagaku Kogyo Kabushiki Kaisha | Method for preventing senescence and increasing bone mass |
| JP2542846B2 (ja) * | 1987-05-22 | 1996-10-09 | 日本臓器製薬株式会社 | 糖尿病治療剤 |
| US4946679A (en) * | 1988-07-25 | 1990-08-07 | Thys Jacobs Susan | Method for the treatment of premenstrual syndrome |
| US4945103A (en) * | 1989-01-17 | 1990-07-31 | Michael Cohen | Method of treating pre-menstrual syndrome |
-
1990
- 1990-10-25 US US07/603,214 patent/US5116828A/en not_active Expired - Fee Related
- 1990-10-26 JP JP02289657A patent/JP3113269B2/ja not_active Expired - Fee Related
- 1990-10-26 EP EP90120567A patent/EP0424954B1/en not_active Expired - Lifetime
- 1990-10-26 ES ES90120567T patent/ES2055845T3/es not_active Expired - Lifetime
- 1990-10-26 AT AT9090120567T patent/ATE104854T1/de not_active IP Right Cessation
- 1990-10-26 DE DE69008476T patent/DE69008476T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69008476D1 (de) | 1994-06-01 |
| DE69008476T2 (de) | 1994-09-01 |
| EP0424954B1 (en) | 1994-04-27 |
| JPH03209328A (ja) | 1991-09-12 |
| EP0424954A1 (en) | 1991-05-02 |
| JP3113269B2 (ja) | 2000-11-27 |
| US5116828A (en) | 1992-05-26 |
| ATE104854T1 (de) | 1994-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE104854T1 (de) | Pharmazeutische zusammensetzung zur behandlung von osteoporose. | |
| CY1110287T1 (el) | Χρηση της ανθρωπινης παραθυρεοειδους ορμονης | |
| IL92007A0 (en) | Pharmaceutical compositions containing gestodene | |
| ATE79271T1 (de) | Pharmazeutische zubereitung zur anwendung fuer die anreicherung von knochenmasse. | |
| BR9402902A (pt) | Hormônio paratiróideo e raloxifeno, compostos e formulação farmacêutica. | |
| IL85523A (en) | Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it | |
| DE19375061I2 (de) | Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung. | |
| BR8801242A (pt) | Processo de preparar uma composicao para fornecer uma quantidade efetiva de uma dose constante de um ingrediente ativo a um animal e a respectiva composicao | |
| ES2031096T3 (es) | Una composicion de implante mejorada a base de estradiol y metodo para su preparacion. | |
| BR9403783A (pt) | Uso de uma composição cosmética | |
| EP0289314A3 (en) | Use of igf-ii in the treatment of bone disorders | |
| ATE220321T1 (de) | Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe | |
| ES2178188T3 (es) | Composiciones antitusigenas que contienen teobromina. | |
| ZA882151B (en) | Binding inducing compositions | |
| EP0230264A3 (en) | Pharmaceutical composition for nasal application, process for its preparation and its use | |
| MX170055B (es) | , "composicion insecticida y procedimiento para su obtencion | |
| DK0613368T3 (da) | Hudregenererende kosmetisk sammensætning | |
| ES2085199B1 (es) | Un procedimiento para la preparacion de una formulacion depot. | |
| ATE311897T1 (de) | Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone | |
| NL300004I1 (nl) | Voor de behandeling van oestrogeentekorten geschikte samenstelling. | |
| AR007059A1 (es) | Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto | |
| AR241632A1 (es) | Procedimiento para preparar una composicion farmaceutica liquida de una 4-aroilimidazol-2-ona. | |
| ES2062227T3 (es) | Composiciones farmaceuticas no parenterales para la insulina. | |
| ES8706441A1 (es) | Procedimiento para preparar una composicion farmaceutica a base de sulpirida y un progestageno. | |
| MX9203784A (es) | Composiciones para el tratamiento de osteoporosis en seres humanos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 424954 Country of ref document: ES |